OTCMKTS:MRNA - Marina Biotech Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $21.44 +1.78 (+9.05 %) (As of 02/19/2019 01:45 AM ET)Previous Close$19.66Today's Range$19.70 - $21.467452-Week Range$13.03 - $22.75Volume2.09 million shsAverage Volume943,922 shsMarket Capitalization$7.05 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Marina Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension. Its clinical development programs include IT-102 and IT-103, a celecoxib program drug candidates for the treatment of combined arthritis pain/hypertension and the treatment of pain requiring a high dose of celecoxib; CEQ508, an oral delivery of small interfering RNA against beta-catenin, combined with IT-102 to suppress polyps in the precancerous syndrome and orphan indication familial adenomatous polyposis; and CEQ508 combined with IT-103 to treat colorectal cancer. The company is headquartered in City of Industry, California. Receive MRNA News and Ratings via Email Sign-up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:MRNA Previous SymbolOTCMKTS:MRNAD CUSIPN/A Webwww.marinabio.com Phone626-964-5788Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees7 Outstanding Shares328,948,000Market Cap$7.05 billion OptionableNot Optionable Marina Biotech (OTCMKTS:MRNA) Frequently Asked Questions What is Marina Biotech's stock symbol? Marina Biotech trades on the OTCMKTS under the ticker symbol "MRNA." How were Marina Biotech's earnings last quarter? Marina Biotech, Inc. (OTCMKTS:MRNA) issued its quarterly earnings data on Friday, May, 18th. The biotechnology company reported ($0.13) earnings per share for the quarter. View Marina Biotech's Earnings History. What price target have analysts set for MRNA? 8 equities research analysts have issued 12-month price targets for Marina Biotech's stock. Their predictions range from $20.00 to $29.00. On average, they expect Marina Biotech's stock price to reach $24.3750 in the next twelve months. This suggests a possible upside of 13.7% from the stock's current price. View Analyst Price Targets for Marina Biotech. What is the consensus analysts' recommendation for Marina Biotech? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marina Biotech in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marina Biotech. Has Marina Biotech been receiving favorable news coverage? Media stories about MRNA stock have been trending positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Marina Biotech earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the next several days. Are investors shorting Marina Biotech? Marina Biotech saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 8,266,866 shares, an increase of 27.6% from the December 31st total of 6,480,950 shares. Based on an average trading volume of 1,237,257 shares, the days-to-cover ratio is presently 6.7 days. Approximately 3.6% of the shares of the stock are short sold. View Marina Biotech's Current Options Chain. Who are some of Marina Biotech's key competitors? Some companies that are related to Marina Biotech include Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE) and Jazz Pharmaceuticals (JAZZ). Who are Marina Biotech's key executives? Marina Biotech's management team includes the folowing people: Mr. Erik Emerson, Chief Commercial Officer & Director (Age 47)Mr. Robert C. Moscato Jr., CEO & Director (Age 42)Mr. Amit Shah, Chief Financial Officer (Age 52)Mr. Mihir Munsif, Chief Operating Officer (Age 55)Dr. Larn Hwang, Chief Scientific Officer (Age 55) When did the company's quiet period expire? Marina Biotech's quiet period expired on Wednesday, January 16th. Marina Biotech had issued 26,275,993 shares in its public offering on December 7th. The total size of the offering was $604,347,839 based on an initial share price of $23.00. During the company's quiet period, underwriters and any insiders involved in the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. Who are Marina Biotech's major shareholders? Marina Biotech's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Canada Pension Plan Investment Board (0.49%), Essex Investment Management Co. LLC (0.00%) and Essex Investment Management Co. LLC (0.00%). Company insiders that own Marina Biotech stock include Joseph W Ramelli and Vuong Trieu. View Institutional Ownership Trends for Marina Biotech. Which major investors are buying Marina Biotech stock? MRNA stock was acquired by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, Essex Investment Management Co. LLC and Essex Investment Management Co. LLC. Company insiders that have bought Marina Biotech stock in the last two years include Joseph W Ramelli and Vuong Trieu. View Insider Buying and Selling for Marina Biotech. How do I buy shares of Marina Biotech? Shares of MRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Marina Biotech's stock price today? One share of MRNA stock can currently be purchased for approximately $21.44. How big of a company is Marina Biotech? Marina Biotech has a market capitalization of $7.05 billion. Marina Biotech employs 7 workers across the globe. What is Marina Biotech's official website? The official website for Marina Biotech is http://www.marinabio.com. How can I contact Marina Biotech? Marina Biotech's mailing address is 17870 CASTLETON STREET SUITE 250, CITY OF INDUSTRY CA, 91748. The biotechnology company can be reached via phone at 626-964-5788 or via email at [email protected] MarketBeat Community Rating for Marina Biotech (OTCMKTS MRNA)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 101 (Vote Outperform)Underperform Votes: 69 (Vote Underperform)Total Votes: 170MarketBeat's community ratings are surveys of what our community members think about Marina Biotech and other stocks. Vote "Outperform" if you believe MRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2019 by MarketBeat.com StaffFeatured Article: What are Bollinger Bands?